Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.

ABSTRACT: Measurable residual disease (MRD; previously termed minimal residual disease) is an independent, postdiagnosis, prognostic indicator in acute myeloid leukemia (AML) that is important for risk stratification and treatment planning, in conjunction with other well-established clinical, cytogenetic, and molecular data assessed at diagnosis. MRD can be evaluated using a variety of multiparameter flow cytometry and molecular protocols, but, to date, these approaches have not been qualitatively or quantitatively standardized, making their use in clinical practice challenging. The objective of this work was to identify key clinical and scientific issues in the measurement and application of MRD in AML, to achieve consensus on these issues, and to provide guidelines for the current and future use o

SUBMITTER: Schuurhuis GJ 

PROVIDER: S-EPMC5865231 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature